Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
VANCOUVER, British Columbia, August 1, 2023 — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in
August 1, 2023
